The low-density lipoprotein receptor–related protein (Lrp)-5 functions as a Wnt coreceptor.
Here we show that mice with a targeted disruption of Lrp5 develop a low bone mass …

Oncolytic viruses and active immunotherapeutics have complementary mechanisms of action
(MOA) that are both self amplifying in tumors, yet the impact of dose on subject outcome is …

The cystic fibrosis transmembrane conductance regulator(CFTR) functions to regulate both
CI − and Na + conductive pathways; however, the cellular mechanisms whereby CFTR acts …

The efficacy and safety of biological molecules in cancer therapy, such as peptides and small
interfering RNAs (siRNAs), could be markedly increased if high concentrations could be …

Self-powered implantable devices have the potential to extend device operation time inside
the body and reduce the necessity for high-risk repeated surgery. Without the technological …

Background Numerous clinical trials and observational studies have investigated various
pharmacological agents as potential treatment for Coronavirus Disease 2019 (COVID-19), but …

Oncolytic viruses are generally designed to be cancer selective on the basis of a single
genetic mutation. JX-594 is a thymidine kinase (TK) gene-inactivated oncolytic vaccinia virus …

Efforts to selectively target and disrupt established tumor vasculature have largely failed to
date. We hypothesized that a vaccinia virus engineered to target cells with activation of the ras…

Fifteen patients with treatment-refractory colorectal cancer were enrolled on a phase 1b study
of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic …

Pexa-Vec (pexastimogene devacirepvec, JX-594) is an oncolytic and immunotherapeutic
vaccinia virus designed to destroy cancer cells through viral lysis and induction of granulocyte-…